Introduction {#s1}
============

Antibodies targeting myelin oligodendrocyte glycoprotein immunoglobulin (MOG-IgG) detected by cell-based assays[@R1] are recognised biomarkers of a subgroup of central nervous system inflammatory demyelinating disorders (CNS IDDs) termed MOG-IgG-associated disorders (MOGAD).[@R2] Single episode and recurrent ON are the most common presentations of MOGAD followed by transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM) and brainstem syndromes or combination of such manifestations.[@R1]

Population-based studies have demonstrated, in aquaporin-4 immunoglobulin (AQP4-IgG)-positive neuromyelitis optica spectrum disorders (NMOSD), that ethnicity plays an important role in determining risk for NMOSD. Afro-Carribeans from Martinique have a threefold higher prevalence of NMOSD compared with Caucasians in Olmsted County, Minnesota.[@R5]

It remains unclear whether ethnicity is a risk factor for the development of MOGAD. Sri Lanka located in South Asia has predominant Sinhalese ethnicity. The AQP4-IgG and MOG-IgG serostatus of CNS IDDs in these populations have not been previously determined.

Patients and methods {#s2}
====================

Serum samples of 726 consecutive Sri Lankan patients undergoing evaluation for suspected IDDs at the National Hospital of Sri Lanka, a tertiary care centre, between January 2013 and March 2018 were tested for AQP4-IgG and MOG-IgG by Clinical Laboratory Improvement Amendments approved flow cytometric assays. Infectious, granulomatous (eg, sarcoidosis) and neoplastic aetiologies were excluded.

MOG-IgG1 serostatus was defined as persistent when seropositivity confirmed at or more than 6 months after the onset attack. Clinical information was available for 550 patients (113 children and 437 adults).

Statistical analysis {#s3}
====================

SAS V.9.4 and JMP V.13 were used. χ^2^ or Fisher's exact tests were applied to compare categorical variables. Continuous data for two patient groups classified by serostatus were analysed by Student's t and rank sum tests. P\<0.05 was deemed statistically significant.

Results {#s4}
=======

Of sera from 726 consecutive patients undergoing evaluation for suspected IDDs at the National Hospital of Sri Lanka, 126 (17.4%) tested positive for MOG-IgG1. Ethnicities were 107 (85%) Sinhalese, 10 (8%) Muslim and 9 (7%) Tamil. For 550 patients with clinical data available, the frequency of MOG-IgG1 seropositivity was higher in paediatric (38.9%; 44 of 113) than adult (18.7%; 82 of 437). Only 36 (5%) tested positive for AQP4-IgG. None were positive for both. Overall, 24% of patients harboured a glial autoantibody biomarker.

The median age of onset for MOGAD was 26 years (range 3--68), younger compared with AQP4-IgG-positive NMOSD patients (median 38 years (range 15--73), p\<0.001). MOGAD had a lower likelihood of relapsing disease compared with AQP4-IgG-positive NMOSD cases (34% vs 64%, p\<0.001). Duration of follow-up of MOGAD was 3.6 years (range 0.12--20) and AQP4-IgG-positive NMOSD was 6.67 years (range 0.67--13.67), p=0.37. The preponderance of female sex was also less (56% vs 86%, p\<0.01) ([table 1](#T1){ref-type="table"}).

###### 

Demographic and clinical features of 126 MOG-IgG1-positive Sri Lankan patients

  Characteristics                                MOG-IgG1-positive patients, N (%)                 
  ---------------------------------------------- ----------------------------------- ------------- ---------------
  Age at onset, years, median (range)            26 (3--68)                          9 (3--18)     33.5 (19--68)
  Sex, female                                    70 (56)                             22 (50)       48 (58)
  Symptoms at onset                                                                                
   Optic neuritis (alone)                        64 (51)                             17 (39)       47 (57)
   Transverse myelitis                           29 (23)                             7 (16)        22 (28)
   ADEM                                          11 (9)                              11 (25)       0 (0)
   Optic neuritis and transverse myelitis        8 (6)                               2 (4)         6 (7)
   Optic neuritis and ADEM                       13 (10)                             7 (16)        6 (7)
   Optic neuritis and intractable hiccups        1 (1)                               0 (0)         1 (1)
  Clinical phenotype at last follow-up                                                             
   Optic neuritis (single or relapsing)          58 (46)                             16 (36)       42 (52)
   Transverse myelitis                           24 (19)                             4 (10)        20 (24)
   ADEM                                          12 (10)                             12 (27)       0 (0)
   NMOSD                                         32 (25)                             12 (27)       20 (24)
  Duration of follow-up, years, median (range)   4 (0.12--20)                        3 (0.5--18)   3 (0.25--20)
  Number of patients with relapsing course       43 (34)                             15 (34)       28 (34)
  Median number of relapse (range)               1 (1--9)                            1 (1--8)      1 (1--9)
  Acute treatments‡                              115 (100)                           44 (100)      82 (100)
  Long-term immunotherapy§                       55 (50)                             18 (45)       38 (53)

The final diagnoses for the 355 MOG-IgG1 seronegative adult cases were in decreasing order of frequency: optic neuritis (133), transverse myelitis (76), MS (45), AQP4-IgG-positive NMOSD (24), CRION (12), ADEM (4) and other (61).

\*Available MRI spine data were available for 33 patients, who presented with transverse myelitis alone and optic neuritis with transverse myelitis. A total of 14 of the 126 patients were initially diagnosed as MS but subsequently tested positive for MOG-IgG.

†Clinical data were available for 550 patients: The final diagnoses for the 69 MOG-IgG1 seronegative paediatric cases were in decreasing order of frequency: transverse myelitis (24), optic neuritis (17), ADEM (8), MS (6), AQP4-IgG-positive NMOSD (4) CRION (1) and other (9).

‡Acute treatments included intravenous methylprednisolone, plasma exchange, immunoglobulin G and combination (data available for 115 patients).

§Long-term immunotherapy included azathioprine, prednisolone, mycophenolate mofetil and combination (data available for 110 patients).

ADEM, acute disseminated encephalomyelitis; CRION, chronic relapsing inflammatory optic neuropathy; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders.

ON at presentation was observed in 88 of 126 (62%) patients and occurred either in isolation (64, unilateral 17 and bilateral 47) or in combination with other demyelinating syndromes (22: ADEM 13; TM 8 and area postrema syndrome 1). About 19% had recurrent ON. For patients presenting with isolated ON, 90% had normal MRI brain outside of the optic nerve.

Of 126 MOGAD cases, only 32 (25%) fulfilled 2015 NMOSD criteria. The duration of disease of these patients was not different from those not fulfilling such criteria (p=0.36).

ADEM at presentation was observed in 24 of 126 (19%) patients and occurred either in isolation (13, 54%) or in combination with ON (ADEM/ON 11, 46%); 18 (75%) of these ADEM cases were children representing 46% (18/39) of all MOGAD children. The adult-onset ADEM cases represent only 6.9% of adult MOGAD patients (6/87).

Thirty-seven patients (29%) presented with TM: 29 (78%) in isolation and 8 (22%) in combination with ON. Just over half (57%) of all TM cases had longitudinally extensive TM on MRI: 6 of 9 (67%) paediatric and 15 of 28 (54%) adult cases.

A total of 43 out of the 121 (34%) had relapsing disease. The duration of follow-up was longer in the relapsers (8 years, range 0.5--20) compared with those monophasic (2 years, range 0.25--5) at last follow-up (p\<0.001). The median time from the first to second attack was 1 year (range 0.25--13 years). Samples from \>6 months postonset (considered evidence of persistent seropositivity) were available in 17 patients: 13 patients (76%) had greater than one attack after median follow-up of 7 years (range 3--17) while 4 patients (24%) remained monophasic after median follow-up of 1 year (range 1--2), p=0.011.

Visual outcome data were available for 59 of 86 MOG-IgG1-positive ON cases with median duration of follow-up of 4 years (range 0.12--20.0): 44 (74%) normal, 8 (14%) mild visual impairment and 7 (12%) severe visual impairment or blind in one eye. All attacks were treated with steroids or immunoglobulin G or plasma exchange. Maintenance immunosuppressant medications (prednisolone, azathioprine, mycophenolate mofetil or, combinations thereof) were used in half of the MOGAD cases ([table 1](#T1){ref-type="table"}). Mobility data were available for 118 patients with median duration of follow-up of 3 years (range 0.25--20 years): 111 (94%) expanded disability status scale (EDSS)\<6, 6 (5%) EDSS 6--8.5 and 1 (1%) had EDSS 10.

Discussion {#s5}
==========

In this clinic-based study of Sri Lankan patients presenting for evaluation for suspected IDDs, MOG-IgG was detected in one of six (17%) patients and was 3.5 times more common than AQP4-IgG (5%). The MOGAD demographics and phenotypic spectrum in Sri Lankan patients were similar to other reported cohorts.[@R1] Age of onset of MOGAD was not different from previous reports.[@R1] Only 25% of MOGAD fulfilled 2015 NMOSD criteria. Persistent MOG-IgG seropositivity predicted a relapsing course, though the findings in this study are limited by the shorter disease duration in the monophasic cases.

Most MOGAD patients (93%) were able to walk independently and 58% had normal vision at last follow-up. Only 8% were blind in one eye and none were blind in both. Such favourable visual outcomes are consistent with other reports.[@R1]
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